Overview
Numoda is the pioneer of a new model for supporting life sciences companies as they move from clinical development of innovative treatments to ultimate relationships with marketing partners.
Our model aligns with both sponsor and vendor needs, addressing the broader issues that active and complex clinical trials face, by providing a single integrated location your entire trial.
The Numoda approach – which has been proven across scores of relationships – calls for Numoda to share the risk with promising life sciences companies by assisting in business functions such as budgeting and logistics, and to apply patented information technologies and management expertise to achieve the successful completion of vital clinical trials.The result is a unique partnership between Numoda’s finance, technology, and trial management specialists and innovative companies that, in the process, become better able to develop life-enhancing and life-saving treatments for the health of consumers of the future.
About Numoda
Numoda is the pioneer of a new model for supporting life sciences companies as they move from clinical development of innovative treatments to ultimate relationships with marketing partners.
Our model aligns with both sponsor and vendor needs, addressing the broader issues that active and complex clinical trials face, by providing a single integrated location your entire trial.
The Numoda approach – which has been proven across scores of relationships – calls for Numoda to share the risk with promising life sciences companies by assisting in business functions such as budgeting and logistics, and to apply patented information technologies and management expertise to achieve the successful completion of vital clinical trials.The result is a unique partnership between Numoda’s finance, technology, and trial management specialists and innovative companies that, in the process, become better able to develop life-enhancing and life-saving treatments for the health of consumers of the future.
About Numoda
Numoda has been engaged by hundreds of organizations seeking
clinical trial management, proprietary technology solutions, business
advisory services and funding—all in service of the development of
innovative therapies and treatments.
Over the past twelve years, we have managed successful engagements for organizations including:
Numoda is seeking opportunities to provide game changing services in the life science sector. As a trusted partner to many leading pharmaceutical companies, Numoda offers expertise in:
About us(Numoda)
Passion for giving organizations superior service and solutions to complete their intended missions
.
Drive to improve every aspect of the life sciences enterprise—from funding, to testing, to partnering for access to commercialization partners and markets.
Three organizations work in harmony and collaborate for improved clinical outcomes and investment results:
Numoda Corporation – integrates every aspect of clinical trial development under The Accountable General Contractor, with unparalleled accountability of all suppliers, groups and participants for the life sciences.
Numoda Technologies, Inc – builds and maintains the patented platforms of integrations, logistics management, and financial oversight for clinical development and efficient trial and data management.
Numoda Capital Innovations – enables life sciences companies to attract capital and partners while investing directly in companies with promising new therapies and treatments.
News At Glance :
Zack's Investment Research(click here)
February 2012
Advaxis Reports Positive Phase II Trial Results
"...The study is designed to assess the safety and efficacy of ADXS-HPV for the treatment of CIN grade 2/3, which is late stage cervical dysplasia that requires surgery to prevent invasive cancer. Numoda Corporation is Advaxis’ strategic partner in the conduction and execution of this trial. "
One Med Place(click here)
January 2012
Advaxis CEO Tom Moore Interviewed by OneMedPlace Regarding Preliminary Data
"Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, reports that Thomas Moore, CEO & Chairman of Advaxis, was interviewed by Malini Chatterjee, Ph.D., Director of Research at OneMedPlace, to discuss the preliminary safety and survival data from the ongoing ADXS-HPV Phase 2 Trial in patients with recurrent/refractory cervical cancer in India that were presented at the World Cancer Immunotherapy Conference in San Diego on January 25, 2012.. "
The Street (click here)
January 2012
Pinnacle Biologics, Inc. Announces The Successful Completion Of A Financing Round
" Led by NUMODA CAPITAL INNOVATIONS, LLC., PINNACLE BIOLOGICS announced today the succesful completion of a financing round, in a combination of Equity, and Debt Conversion. "
Med City News (click here)
December 2011
Numoda life science investment arm collaborates with stem cell technology company
- By Stephanie Baum
"Philadelphia technology company Numoda‘s life science investment arm, Numoda Capital Innovations, has collaborated with IntelliCell Bioscience, a New York-based company seeking to harvest adult adipose stem cells derived from fat in a cost-effective manner. "
Dow Jones Venture Wire (click here)
June 2011
With Drugs In Doubt, Some Biotechs Are Selling Out
- By Brian Gormely
"...Numoda now plans to develop Vitreosolve in the primary indication of vitreomacular adhesion and the secondary indication of inducing a posterior-vitreous detachment in the treatment of diabetic retinopathy. The firm plans new, placebo-controlled studies and is consulting drug-makers to find other ways to groom Vitreosolve for a sale. It aims to speed the auctioning process through technology from an affiliate, Numoda Technologies Inc., that enables potential bidders to see trial data as they are generated."
Dow Jones Venture Wire (click here)
March 2011
Numoda Capital Buys VitreoRetinal Assets, Seeks To Revive Vision Drug
- By Brian Gormely
"Numoda Capital Innovations is reviving an effort to develop a drug for the blinding disease diabetic retinopathy that stalled in the hands of venture-backed VitreoRetinal Technologies Inc."
January 2011
After announcing positive top-line results from a large, global Phase III clinical trial that Numoda managed and partially funded through an investment, stakeholders experienced a 46% gain in share price. Since the study began, $83MM in market value was created for our client, as well as a significant licensing deal.
If you would like to learn more about how these results can benefit you please visit us at the JP Morgan 2011 Healthcare Conference. Contact Christopher Mather, SVP Business Affairs, for appointments.
Crain's Detroit Business (click here)
October 2010
MichBio Expo attendees hear ways to get VC funding for startups
- By Shawn White
..."There has been a decrease in number of biotech and medical investments overall," said Mary Schaheen, CEO of Philadelphia-based Numoda Corp. "But there have been a lot of very creative sources for funds: grants, alliances, high net worth investors and consolidation."...
Pharmawire(click here)
October 2010
Marina retains Numoda for Phase Ib/IIa trial of lead compound; open to contact from other CROs for pivotal Phase IIb - CEO
-by Anusha Kambhampaty
...The company will work with Numoda for the 30 patient trial that will assess the knock-down of betacatenin
in the epithelial cells of the small and large intestine regions where beta-catenin is
known to be dysregulated in FAP...
World Market Media(click here)
July 2010
Provectus Scores Points with Numoda Capital
- By Steven Michael King
... Numoda’s TruPoints platform already has an excellent reputation for helping numerous development stage biotech companies secure big pharma licensing agreements...
MedCityNews (click here)
July 2010
Cleveland Clinic, Numoda partner to speed brain drugs to market
- By Mary Vanac
...The goal is to speed effective neurological drugs to market and quickly weed out those that don’t work, while lowering the cost of drug development. ....
July 2010
Dow Jones Venture Wire (click here)
June 2010
Numoda Forms Cleveland Clinic Alliance; Deal Will Feed Venture Arm
- By Brian Gormely
...Numoda said its technology and services can also help companies catch and fix problems that are occurring in clinical studies. Numoda will also provide researchers at Cleveland Clinic's Neurological Institute with information systems, reporting engines and administrative tools to help improve patient recruitment, budgeting and data flow. ....
Venture Capital Dispatch - WSJ (click here)
January 2010
JPMorgan Conference Lifts Biotech VC Hopes For Pharma Deals
- By Brian Gormely
...Pharmaceutical companies at the conference were looking to spin products out as well as bring them in, said Terrance McGovern, managing director, Numoda Capital Innovations, an investment affiliate of Numoda Corp. ....
Dow Jones Venture Wire (click here)
August 2009
MediQuest Therapeutics Takes Streamlined Route To VC Liquidity
- By Brian Gormely
...Numoda Capital also works with these companies to help them find strategic partners. The group aims to connect MediQuest with pharmaceutical companies interested in licensing Vascana and other pipeline drugs....
The Wall Street Journal (click here)
April 2009
Clinical Trials Manager Heads Into VC
- By Scott Austin
...Numoda’s track record of helping companies reduce the cost and risk of drug development should appeal to investors...
Dow Jones Venture Wire (click here)
April 2009
Numoda Seeks $150M Debut Health Fund
- By Brian Gormely
...“From a financial perspective, we can de-risk the process,” Schaheen said. “Our job is to get time, quality and
money in balance.”...
C.E. Unterberg Business Analyst (click here)
June 2007
October 2006
...Managing risk and rewarding risk taking, integrating the skills and capabilities that reside in a range of disciplines...
Charite Artificial Spinal Replacement Disc approved
by U.S. regulators within a year. (click here)
...for a recently concluded medical device study, sponsored by DePuy Spine (formerly Link Spine Group). This new prosthesis is an artificial spinal disc that provides a wider range of motion for the patient. The procedure is expected to replace spinal fusion surgery.
Over the past twelve years, we have managed successful engagements for organizations including:
- Biotech—both startups and mature organizations
- Biopharma—seeking to both in-license and out-license
- Not-for-profit organizations sponsoring clinical trials
- Life sciences firms in need of business consulting and funding
- Clinical Research Organizations looking for integration
- Investors and corporate strategic funds seeking opportunities to capture upside value in late-stage drugs
Numoda is seeking opportunities to provide game changing services in the life science sector. As a trusted partner to many leading pharmaceutical companies, Numoda offers expertise in:
- Support safety and efficacy in clinical trials
- Eliminating conduct risks that cause good drugs to fail – regulatory hurdles
- Providing financial oversight to control trial costs
- Obtaining datalock within 48 hours
- Identifying potential strategic partners
About us(Numoda)
Our Values
Commitment to a new model of efficiency, cost
effectiveness, and success for the development of revolutionary
therapies and treatments for the benefit of patients worldwidePassion for giving organizations superior service and solutions to complete their intended missions
.
Drive to improve every aspect of the life sciences enterprise—from funding, to testing, to partnering for access to commercialization partners and markets.
Who We Are
Numoda Corporation is a fifteen-year-old company headquartered in Philadelphia, with operations in 50 countries. Three organizations work in harmony and collaborate for improved clinical outcomes and investment results:
Numoda Corporation – integrates every aspect of clinical trial development under The Accountable General Contractor, with unparalleled accountability of all suppliers, groups and participants for the life sciences.
Numoda Technologies, Inc – builds and maintains the patented platforms of integrations, logistics management, and financial oversight for clinical development and efficient trial and data management.
Numoda Capital Innovations – enables life sciences companies to attract capital and partners while investing directly in companies with promising new therapies and treatments.
News At Glance :
Zack's Investment Research(click here)
February 2012
Advaxis Reports Positive Phase II Trial Results
"...The study is designed to assess the safety and efficacy of ADXS-HPV for the treatment of CIN grade 2/3, which is late stage cervical dysplasia that requires surgery to prevent invasive cancer. Numoda Corporation is Advaxis’ strategic partner in the conduction and execution of this trial. "
One Med Place(click here)
January 2012
Advaxis CEO Tom Moore Interviewed by OneMedPlace Regarding Preliminary Data
"Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, reports that Thomas Moore, CEO & Chairman of Advaxis, was interviewed by Malini Chatterjee, Ph.D., Director of Research at OneMedPlace, to discuss the preliminary safety and survival data from the ongoing ADXS-HPV Phase 2 Trial in patients with recurrent/refractory cervical cancer in India that were presented at the World Cancer Immunotherapy Conference in San Diego on January 25, 2012.. "
The Street (click here)
January 2012
Pinnacle Biologics, Inc. Announces The Successful Completion Of A Financing Round
" Led by NUMODA CAPITAL INNOVATIONS, LLC., PINNACLE BIOLOGICS announced today the succesful completion of a financing round, in a combination of Equity, and Debt Conversion. "
Med City News (click here)
December 2011
Numoda life science investment arm collaborates with stem cell technology company
- By Stephanie Baum
"Philadelphia technology company Numoda‘s life science investment arm, Numoda Capital Innovations, has collaborated with IntelliCell Bioscience, a New York-based company seeking to harvest adult adipose stem cells derived from fat in a cost-effective manner. "
Dow Jones Venture Wire (click here)
June 2011
With Drugs In Doubt, Some Biotechs Are Selling Out
- By Brian Gormely
"...Numoda now plans to develop Vitreosolve in the primary indication of vitreomacular adhesion and the secondary indication of inducing a posterior-vitreous detachment in the treatment of diabetic retinopathy. The firm plans new, placebo-controlled studies and is consulting drug-makers to find other ways to groom Vitreosolve for a sale. It aims to speed the auctioning process through technology from an affiliate, Numoda Technologies Inc., that enables potential bidders to see trial data as they are generated."
Dow Jones Venture Wire (click here)
March 2011
Numoda Capital Buys VitreoRetinal Assets, Seeks To Revive Vision Drug
- By Brian Gormely
"Numoda Capital Innovations is reviving an effort to develop a drug for the blinding disease diabetic retinopathy that stalled in the hands of venture-backed VitreoRetinal Technologies Inc."
January 2011
After announcing positive top-line results from a large, global Phase III clinical trial that Numoda managed and partially funded through an investment, stakeholders experienced a 46% gain in share price. Since the study began, $83MM in market value was created for our client, as well as a significant licensing deal.
If you would like to learn more about how these results can benefit you please visit us at the JP Morgan 2011 Healthcare Conference. Contact Christopher Mather, SVP Business Affairs, for appointments.
Crain's Detroit Business (click here)
October 2010
MichBio Expo attendees hear ways to get VC funding for startups
- By Shawn White
..."There has been a decrease in number of biotech and medical investments overall," said Mary Schaheen, CEO of Philadelphia-based Numoda Corp. "But there have been a lot of very creative sources for funds: grants, alliances, high net worth investors and consolidation."...
Pharmawire(click here)
October 2010
Marina retains Numoda for Phase Ib/IIa trial of lead compound; open to contact from other CROs for pivotal Phase IIb - CEO
-by Anusha Kambhampaty
...The company will work with Numoda for the 30 patient trial that will assess the knock-down of betacatenin
in the epithelial cells of the small and large intestine regions where beta-catenin is
known to be dysregulated in FAP...
World Market Media(click here)
July 2010
Provectus Scores Points with Numoda Capital
- By Steven Michael King
... Numoda’s TruPoints platform already has an excellent reputation for helping numerous development stage biotech companies secure big pharma licensing agreements...
MedCityNews (click here)
July 2010
Cleveland Clinic, Numoda partner to speed brain drugs to market
- By Mary Vanac
...The goal is to speed effective neurological drugs to market and quickly weed out those that don’t work, while lowering the cost of drug development. ....
July 2010
Dow Jones Venture Wire (click here)
June 2010
Numoda Forms Cleveland Clinic Alliance; Deal Will Feed Venture Arm
- By Brian Gormely
...Numoda said its technology and services can also help companies catch and fix problems that are occurring in clinical studies. Numoda will also provide researchers at Cleveland Clinic's Neurological Institute with information systems, reporting engines and administrative tools to help improve patient recruitment, budgeting and data flow. ....
Venture Capital Dispatch - WSJ (click here)
January 2010
JPMorgan Conference Lifts Biotech VC Hopes For Pharma Deals
- By Brian Gormely
...Pharmaceutical companies at the conference were looking to spin products out as well as bring them in, said Terrance McGovern, managing director, Numoda Capital Innovations, an investment affiliate of Numoda Corp. ....
Dow Jones Venture Wire (click here)
August 2009
MediQuest Therapeutics Takes Streamlined Route To VC Liquidity
- By Brian Gormely
...Numoda Capital also works with these companies to help them find strategic partners. The group aims to connect MediQuest with pharmaceutical companies interested in licensing Vascana and other pipeline drugs....
The Wall Street Journal (click here)
April 2009
Clinical Trials Manager Heads Into VC
- By Scott Austin
...Numoda’s track record of helping companies reduce the cost and risk of drug development should appeal to investors...
Dow Jones Venture Wire (click here)
April 2009
Numoda Seeks $150M Debut Health Fund
- By Brian Gormely
...“From a financial perspective, we can de-risk the process,” Schaheen said. “Our job is to get time, quality and
money in balance.”...
C.E. Unterberg Business Analyst (click here)
June 2007
...Enrollment nearing completion....
Harvard Business Review (click here)October 2006
...Managing risk and rewarding risk taking, integrating the skills and capabilities that reside in a range of disciplines...
Charite Artificial Spinal Replacement Disc approved
by U.S. regulators within a year. (click here)
...for a recently concluded medical device study, sponsored by DePuy Spine (formerly Link Spine Group). This new prosthesis is an artificial spinal disc that provides a wider range of motion for the patient. The procedure is expected to replace spinal fusion surgery.
